Royalty Report: Diagnostic, Drugs, Cancer – Collection: 369238

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Diagnostic
  • Drugs
  • Cancer
  • Drug delivery
  • Drug Discovery
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 369238

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

Licensor grant a non-exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
Licensor owns, controls and/or has the right to sublicense the Licensed Subject Matter.

The Licensed subject matter patents include
—  MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Ovarian Cancer using a Real-Time PCR Platform;
—  Methods and Materials Related to Ovarian Cancer;
—  MicroRNA Signatures in Human Ovarian Cancer;
—  Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155; and,
—  Ultra conserved Regions encoding ncRNAs.

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
MicroRNAs have been the subject of study by my laboratory for more than a decade, and Licensee's work and the work of others has shown that the dysregulation of these molecules plays a critical role in the development of cancer and other diseases,  The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat prostate, ovarian, colon and lung cancers.

The Exclusive Field of Use is for the diagnosis, prognosis and therapy/treatment of ovarian cancer.

IPSCIO Record ID: 372423

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

University grants a non-exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
The patents include
– MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers;
– Compositions and Methods for the Diagnosis and Therapy of BCL2-Associated Cancers;
– MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders;
– Ultraconserved Regions Encoding ncRNAs; and,
– Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155.

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
The Exclusive Field of Use for the diagnosis, prognosis and therapy/treatment of prostate cancer.

IPSCIO Record ID: 344534

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

Licensor grants a non- exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
Licensor owns, controls and/or has the right to sublicense the Licensed Subject Matter which is the licensed patents and technology.

The patents include
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
Compositions and Methods for the Diagnosis and Therapy of BCL2-Associated Cancers
MicroRNA Based Methods and Compositions for the Diagnosis and Treatment of Colon Related Diseases
Ultraconserved Regions Encoding ncRNAs
Methods for Identifying Fragile Histidine Triad (Fhit) Interaction and Uses Thereof
Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155
Materials and Methods Related to MicroRNA-21. Mismatch Repair, And Colorectal Cancer
Mutator activity induced by microRNA-155 (miR-155) Links Inflammation and Cancer
Methods and Compositions Related to miR-21 & miR-29a and Cancer Metastasis
Mechanism of NSAID Chemoprevention in Colorectal Cancer

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
Exclusive Field of Use is for the diagnosis, prognosis and therapy/treatment of colon cancer.

IPSCIO Record ID: 344535

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

Licensor grants a non- exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
Licensor owns, controls and/or has the right to sublicense the Licensed Subject Matter, meaningthe patents and technology.

Patents include
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers,
MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer,
Material and Methods Useful for Affecting Tumor Cell Growth, Migration, and Invasion,
Ultraconserved Regions Encoding ncRNAs,
Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155,
Methods for Reverting Methylation by Targeting DNMT3A and DNMT3B,
Methods of Identifying Fragile Histidine Triad (FHIT) Interaction and Uses Thereof,
Methods and Compositions Related to miR-21 and miR-29a, Exosome Inhibition and Cancer Mestastsis,
miRNAs Useful to Reduce Lung Cancer Turmorigenesis and Chemotherpay Resistance and Related Compositions and Methods,
Mutator Activity Induced by microRNA-155 (miR-155) Links Inflammation and Cancer, and,
Use of miR-494 to Modulate TRAIL-induced Apoptosis through BIM Down-regulation.

Licensed Product means any product, apparatus, kit, test having a panel of either a single nucleotide or two or more nucleotides in combination or component thereof whose manufacture, use, sale, offer for sale or import is Covered By any claim or claims included within the Patent Rights or incorporates any Technology Rights, or which is made using a Licensed Process or another Licensed Product.

Field of Use
The Exclusive Field of use is for the diagnosis, prognosis and therapy/treatment of lung cancer.

IPSCIO Record ID: 372424

License Grant
Licensor, a not-for-profit corporation formed to manage intellectual property developed at a university, grants Licensee an exclusive license under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

University grants a non-exclusive sublicense under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field of Use in the Territory and to perform Licensed Services in the Field of Use in the Territory.

License Property
The patents include
– Novel Liposomal Formulation for Drug Delivery;
– Nanoparticle Compositions for Nucleic Acid Delivery; and,
– Lipid Nanoparticle Compositions and Methods of Making and Methods of Using the Same.

OSU Products means Licensed Products and/or Licensed Services that also qualify as Licensed Products and/or Licensed Services under a separate patent and technology license agreement.

Non-OSU Products means Licensed Products and/or Licensed Services that do not also qualify as Licensed Products and/or Licensed Services under a separate patent and technology license agreement (as defined as such under said separate license agreement) with Licensor.

Field of Use
The Field of Use is the Exclusive use of lipid nanoparticles, also referred to as quaternary and tertiary amine-cationic lipids QTsome, small peptide lipid nanoparticle-gramicidin and/or JTS-1 SPLN-G, and proteinase K-coated liposome PrKsome, as more particularly defined in Patent Rights/Technology Rights for the diagnosis, treatment, prevention and amelioration of human diseases and conditions.

Excluded Fields of Use include but are not limited to
– Use of the following technology described in Patent Rights/Technology Rights L-CAN – lipid-coated albumin nanoparticles (also referred to as Hyper-cationized albumin-polycation conjugates, APC, and L-CAN).

IPSCIO Record ID: 26038

License Grant
The Licensor grants to Licensee a non-exclusive right and license, without the right to sublicense, under the Licensed Patent Rights as licensed to Licensor pursuant to the Original Agreement, to make, have made, use, sell, offer for sale and import Licensed Products and to practice the Licensed Methods in the Field in the Territory to the extent permitted by law.
License Property
The Licensor is involved in the discovery, development and commercialization of medical tests that diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. Field shall mean in-vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.
Field of Use
The Licensee is a provider of clinical laboratory services.

Field” shall mean in vitro diagnostics for screening, diagnosing and monitoring for Ovarian Cancer in humans in the form of OVA1 tests.

IPSCIO Record ID: 362448

License Grant
German Licensor grants to Licensee during the Term a co-exclusive, worldwide, royalty-bearing license under the Licensors Institute Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, offer for sale, sell and have sold Licensed Products, and to develop, perform, have performed, offer for sale, sell and have sold Licensed Services, each in the Field. Licensee shall have the right to grant sublicenses to the rights granted to it under this Agreement to Third Parties, without seeking consent from Licensor as long as they comply with the terms in the Agreement.
License Property
MPG Patent Rights relate to certain microRNA (Small expressed RNA molecules) sequences discovered by scientists of Licensor.

microRNAs are naturally occurring ribonucleic acid ('RNA') molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of microRNAs is directly linked to many diseases. Furthermore, many different infectious pathogens interact and bind to host microRNA to survive. To date, over 500 microRNAs have been identified in humans, each of which can bind to multiple messenger RNAs that control key aspects of cell biology. Since many diseases are multi-factorial, involving multiple targets and pathways, the ability to modulate multiple pathways by targeting a single microRNA provides a new therapeutic approach for treating complex diseases.

Licensors Institute Patent Rights shall mean
US Patent Application No. [10/490,955] filed [15-09-2004] (resulting from the PCT appl.)

Licensed Products shall mean any product (i) that, or the development, manufacture, use or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the Licensors Institute Patent Rights, or (ii) which is developed or manufactured by using a Licensed Process or that, when used, practices a Licensed Process. For the purpose of this Agreement, diagnostic kits shall be considered as Licensed Products, and Net Sales of diagnostic kits shall be considered as Net Sales of Licensed Products, if and to the extent such diagnostic kits contain Licensed Products as a diagnostically active product component, together with other diagnostically non-active product components (including without limitation buffers, purification components, or hardware such as tubes, plates, glassware).

Field of Use
microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. We believe we have assembled the leading position in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes.

Field shall mean sale and use of Licensed Products, or performance and sale of Licensed Services, for
(a) Licensee’s internal and collaborative research and development purposes, and
(b) Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.